AsMedic has developed innovative personalized inhalers for Asthma and COPD. The inhaler adjusts the optimal right drug dosage following the patient measurement and inhalation at any given time.
BestBrain - effective cognitive self-care. BestBrain has been created to offer effective and clinically proven cognitive enhancement solutions that can be used autonomously by consumers in the comfort of their home. The company provides products for treating conditions like Alzheimer's and Autism. In January 2019, BestBrain will be initiating a clinical trial with early Alzheimer (MCI) patients of Clalit, Israel’s largest health organization.
Betalin Therapeutics Ltd is a preclinical stage company developing an innovative and breakthrough therapy for diabetes treatment. This game changing technology aims to replace insulin therapy for millions of patients worldwide. Elaborating a bit more on what we do, the biggest advantage of Betalin Therapeutics is that we can create a completely natural biological micro-scaffold, providing the most optimal environment for cells to grow and function properly. The experimental data shows that the performance of and sustainability of the cells on this scaffold (i.e. Engineered Micro Pancreas, EMP) have an overall leading competitive advantage compared to similar products! In the future, we can even use these micro-scaffolds to create different types of miniature organs.
Carevature Medical Ltd. is a privately held medical device company, dedicated to the development of advanced orthopedic surgery solutions. Carevature Medical was founded in 2011 and is headquartered in Rehovot, Israel. Carevature is now focused on its flagship product for spinal indications, Dreal™, the first and only curved device powerful enough to efficiently cut bone and small enough to be used in spine surgery and neurosurgery. This unique design allows for better access and less trauma, resulting in better outcomes for both patients and the healthcare system.
Dune developed radiofrequency spectroscopy (RFS) to characterize tissue and determine in real time as cancerous or not. RFS has applications in all solid tissue cancers for accurate biopsy, for complete surgical removal of cancer tissue, and for targeted therapy. First product, MarginProbe for reducing the need for second surgeries in breast cancer surgery, is PMA – FDA approved, recently received a CPT code, at commercial stage, with over 18,000 procedures completed. Second product for biopsy is entering in-vivo trials.
With more than 15 million patients in Europe and in the United States, Heart failure is associated with tremendously high healthcare costs and remains the largest unmet clinical need in the cardiovascular world.
Enopace Biomedical Ltd. is developing an innovative device to treat heart failure patients. Enopace's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload.
Future Crops uses technology and sophisticated agricultural expertise to grow crops in a fully controlled environment. We use breakthrough technologies that are tailored-made to our vertical farm. We offer the purest, cleanest products that are completely pesticide free, with a longer shelf life and consistent flavour from the same source. We stay true to what Nature intended.
HIL is developing a new class of ultra-compact, high-performance cancer Proton Therapy systems. We bring 21st-century technology – nano-tech, high-intensity lasers and advanced magnetics – to a field largely dominated by tech from the 1930’s and 1940’s. Thus HIL is paving the way, for the first time, to truly cost-effective proton therapy solutions. HIL Applied Medical, Ltd. is a privately held company, funded by the Hebrew University in Jerusalem, Israel’s Office of the Chief Scientist and wide, global base of private investors. We are headquartered in Jerusalem, Israel.
With over 25 years of experience and expertise in shockwave therapy solutions, Medispec continuously introduces competitive systems and technological breakthroughs to the market. The company specializes in shockwave-based systems for urology, cardiovascular and orthopedics applications. Medispec services clinics, medical centers and hospitals in over 80 countries worldwide. All of the company’s systems offer modular design, versatility, ease of use and high degree of mobility, for delivering innovative technology in a fast and efficient manner.
Metabomed is developing a therapeutic strategy based on new drugs that inhibit metabolic enzymes which are vital for cancer cells’ survival. Metabomed identifies reprogrammed metabolic pathways specific and essential to cancer cells with genetically-enforced metabolic alterations. Those “induced essential” metabolic pathways uniquely support the growth and survival of cancer cells.
MinInvasive has developed the OmniCuff System – an innovative device enabling arthroscopic, transosseous rotator cuff repair. The device provides the advantages of minimally invasive transosseous repair in a disposable device and eliminates the need for suture anchors. The company completed a successful clinical feasibility study in leading medical centers in the US, with excellent clinical results and high patient and surgeon satisfaction and has initiated a limited market release throughout the US. MinInvasive plans to gradually expand the availability of the device in the US.
MinInvasive entered into a strategic partnership with MicroPort Scientific Corporation to obtain CFDA approval for the OmniCuff system.
MobileODT is reimagining medical visualization technology to enhance women’s health. Combining advanced imaging, data and software applications, MobileODT is saving lives by enabling early cancer detection. The flagship EVA System mobile colposcope is in use in 27 countries and in 50 USA health systems. It allows providers to visualize the cervix, document exams, add annotations and filters directly to cervical images, and collaborate with peers remotely. The EVA System has application for clinical colposcopy and forensic imaging. MobileODT is constantly evolving, adapting it’s products to a variety of clinical settings and is currently exploring the integration of AI for cancer detection.
Nano-Retina is developing a miniature artificial retina to restore vision for people who are blind due to retinal degeneration. The advanced miniature device is implanted in a minimally invasive technique under local anesthesia, and provides superior vision resolution due to its 600 proprietary electrodes and 3DNi™ technology.
Net Ninjas is a decentralized service aggregator. Projects can integrate with the Net Ninja’s platform allowing enterprise customers to access them through a cloud and service agnostic API. Starting with a decentralized proxy and video transcoding, Net Ninjas will allow open source projects to run the needed infrastructure for their services in the background of willing participants phones, computers, or GPU’s during underutilized hours and earn rewards.
Neteera is a Jerusalem-based start-up founded in 2015 by a group of hi-tech veteran executives, including the CEO of Mobileye (NYSE: MBLY) Aftermarket, Isacc Litman. Neteera's contact-free vital sign sensing system is based on a combination of two disruptive technologies - proprietary algorithms (that enable tracking vitals in motion) and a digital SMD micro-radar (sub-THz). Uniquely, Neteera's solution can deliver full functionality in real-world environments, thanks to motion-compensation algorithms. This enables seamless monitoring of the human well-being status even in challenging environments such as in a moving vehicle.
Neurolief brings to market a next generation digital health therapeutics technology for brain neuromodulation – the Relivion™. Relivion™ is a groundbreaking Digital Health Therapeutics head mounted device, designed to effectively modulate large nerve branches in the head and thereby affects brain regions which are involved in control and modulation of pain and mood. It provides a highly effective, side-effects free treatment for the hundreds of millions of patients worldwide which suffer from Migraine and Depression. The Relivion™ Digital Health Therapeutics system integrates the electronic head mounted device, a dedicated mobile application and a cloud database that gather and analyze data to optimize brain neuromodulation and provide individualized treatment. Future indications in the pipeline include ADHD and Insomnia. Serial entrepreneurs with proven success in the Neuromodulation space.
Nuance Hearing designs, develops and markets breakthrough Selective Noise Cancellation (SNC) technology and devices, addressing a variety of attention and hearing disorders. Especially effective in noisy settings like classrooms, lecture halls, open spaces, restaurants and airports, SNC enables users to selectively tune out the background noise and focus on one speaker.
Nucleix develops, manufactures and sales diagnostic liquid biopsy assays for early detection of cancer based on its proprietary biochemistry and machine learning technology. Nucleix assays have the best cost-performance.
Nutritional Growth Solutions develop specific, clinically tested nutrition products for children. Our clinically tested shakes and bars are packed with ingredients that promote growth, and are already consumed by children worldwide. With our formulas, we strive to help children live more confident, happy, and successful lives.
PlasFree focus on the development of an innovative medical device ClearPlasma™ that modifies human plasma to improve treatment for massive bleeding. ClearPlasma™ effectively and specifically extracts Fibrinolytic proteins that are responsible for dissolving blood clots. By doing so, ClearPlasma™ modifies the human plasma generating improved plasma that is more prone to coagulation. Thus, our product aims to revolutionize the treatment of massive bleeding and to enable safe and effective treatment to massive bleeding around the world.
PRC Biomedical develops and manages trials of innovative diagnostic KIT that will determine blood quality level. It will be able to match specific blood unit to a specific patient prior to transfusion as well as to determine the maximum storage time of any donated blood unit.
Q2Pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR) bacteria to be used in conjunction with commonly used antibiotics or as stand-alone medications.
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, there is significant reduction of fat tissue for long time period.
Regenera Pharma, a clinical stage company, develops RPh201, a drug product for the treatment of neurological disorders. RPh201 is a well-defined botanical extract that has been observed to regenerate neural cells and restore function in preclinical and clinical studies. Regenera is currently running a Phase 3 trial in NAION (Nonarteritic Anterior Ischemic Optic Neuropathy) in the U.S. and a Phase 2 trial in Alzheimer Disease in Canada. Results are expected by the end of 2019. Regenera has a strong IP portfolio, consisting of 9 family patents that cover the drug’s use and its composition . CMC development plan is supported by the FDA. Regenera’s dedicated team, made up of highly experienced industry veterans, is working tirelessly and meticulously to achieve the Company’s goal.
Silenseed LTD is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’ novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.
Valcare Medical is dedicated to providing innovative minimally-invasive technologies for the treatment of mitral and tricuspid regurgitation. Its product line includes solutions for the repair and replacement of the mitral valve as well as the repair of the tricuspid valve Our breakthrough mitral valve treatment platform is based on a D-shaped ring which serves both as a docking station for Valcare’s unique replacement prosthesis, and as a highly-effective tool for mitral annulus repair. Our mitral repair and replacement systems as well as our tricuspid repair solution establish Valcare as a leader in valve care, a responsibility we very much take to heart. https://www.valcaremedical.com/
Virility Medical is an Israeli startup founded in 2016. Virility’s vPatch is an electrical stimulation skin patch for the treatment of premature ejaculation and climax control. The vPatch neuromodulates the activity of the pelvic-floor muscles during intercourse and postpone ejaculation. The vPatch is intended for single-use and can be discarded after use.